Ryvu Therapeutics SA (RVU) - Total Liabilities

Latest as of December 2025: zł170.60 Million PLN ≈ $46.95 Million USD

Based on the latest financial reports, Ryvu Therapeutics SA (RVU) has total liabilities worth zł170.60 Million PLN (≈ $46.95 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Ryvu Therapeutics SA (RVU) cash flow conversion to assess how effectively this company generates cash.

Ryvu Therapeutics SA - Total Liabilities Trend (2010–2025)

This chart illustrates how Ryvu Therapeutics SA's total liabilities have evolved over time, based on quarterly financial data. Check RVU asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Ryvu Therapeutics SA Competitors by Total Liabilities

The table below lists competitors of Ryvu Therapeutics SA ranked by their total liabilities.

Company	Country	Total Liabilities
Paragon Care Limited F:PXS	Germany	€1.06 Billion
Detection Technology OY HE:DETEC	Finland	€25.68 Million
Ecomate Holdings Bhd KLSE:0239	Malaysia	RM65.68 Million
Merafe JSE:MRF	South Africa	ZAC1.10 Billion
Modiv Inc NYSE:MDV	USA	$294.77 Million
Hyundai Pharm KO:004310	Korea	₩85.40 Billion
Laramide Resources Ltd AU:LAM	Australia	AU$6.75 Million
Euroapi SAS PA:EAPI	France	€488.50 Million

Liability Composition Analysis (2010–2025)

This chart breaks down Ryvu Therapeutics SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RVU stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.26	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	3.17	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.76	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Ryvu Therapeutics SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Ryvu Therapeutics SA (2010–2025)

The table below shows the annual total liabilities of Ryvu Therapeutics SA from 2010 to 2025.

Year	Total Liabilities	Change
2025-12-31	zł170.60 Million ≈ $46.95 Million	-27.37%
2024-12-31	zł234.89 Million ≈ $64.65 Million	+63.56%
2023-12-31	zł143.61 Million ≈ $39.52 Million	+9.14%
2022-12-31	zł131.59 Million ≈ $36.21 Million	+121.55%
2021-12-31	zł59.39 Million ≈ $16.35 Million	-17.42%
2020-12-31	zł71.92 Million ≈ $19.79 Million	+13.92%
2019-12-31	zł63.13 Million ≈ $17.38 Million	+3.77%
2018-12-31	zł60.84 Million ≈ $16.74 Million	+53.72%
2017-12-31	zł39.58 Million ≈ $10.89 Million	+18.46%
2016-12-31	zł33.41 Million ≈ $9.19 Million	+81.95%
2015-12-31	zł18.36 Million ≈ $5.05 Million	+4.63%
2014-12-31	zł17.55 Million ≈ $4.83 Million	+18.19%
2013-12-31	zł14.85 Million ≈ $4.09 Million	+51.28%
2012-12-31	zł9.82 Million ≈ $2.70 Million	+62.45%
2011-12-31	zł6.04 Million ≈ $1.66 Million	-31.08%
2010-12-31	zł8.77 Million ≈ $2.41 Million	--

About Ryvu Therapeutics SA

WAR:RVU Poland Biotechnology

Market Cap

$152.71 Million

zł554.88 Million PLN

Market Cap Rank

#17578 Global

#122 in Poland

Share Price

zł24.00

Change (1 day)

+2.56%

52-Week Range

zł20.70 - zł34.30

All Time High

zł75.00